Patient characteristics
| Patient | Sex |
Age (years) |
Presenting arrhythmia (CL in ms) | Circumstances |
LVEF (%) | AAR before implant | AAR after implant |
| 1 | Male | 54 | VT (295 ms) | Rest | 59 | Amio, flec, mex, sot | Sot |
| 2 | Male | 11 | VT (260 ms) | Exercise | 39 | Sot | Sot |
| 3 | Male | 54 | VT (270 ms) | Rest | 42 | Amio, prop, phen, sot | Prop, phen, cel |
| 4 | Male | 34 | VT (250 ms) | Exercise | 61 | Amio | Sot |
| 5 | Female | 19 | VF | Exercise | 71 | – | Sot, met |
| 6 | Male | 34 | VF | Exercise | 69 | – | Sot, amio |
| 7 | Male | 30 | VF | Exercise | 63 | – | Sot |
| 8 | Male | 63 | VT (280 ms) | Exercise | 62 | – | – |
| 9 | Male | 22 | VT (270 ms) | Exercise | 72 | Sot | Sot |
AAR, antiarrhythmic drugs; amio, amiodarone; cel, celiprolol; CL, cycle length; flec, flecainide; LVEF, left ventricular ejection fraction; met, metoprolol; mex, mexiletine; phen, phenytoin; prop, propafenone; sot, sotalol; VT, ventricular tachycardia; VF, ventricular fibrillation.